Multiple drug use is very common in the elderly， which will significantly increase drug interactions and adverse drug reactions. Cardiovascular disease complicated with neuropsychiatric disease is the most common multi-disease comorbidity among the elderly， and it is also one of the disease combinations involving the most multiple drug use. In order to reduce the adverse clinical outcomes of the elderly in China， Chinese Society of Clinical Pharmacy of Chinese Medical Association organized relevant experts to develop Expert Consensus on Risk Prevention and Control of Multiple Drug Use in Elderly Patients with Cardiovascular Diseases and Neuropsychiatric Diseases in China by using foreign drug use risk assessment tools and combining relevant evidence-based results， and further promote its application in clinical disease treatment practice to reduce the adverse clinical outcomes of the elderly in China.

In recent years,navigated transcranial magnetic stimulation(nTMS)has developed rapidly in clinical application and scientific research in the field of psychiatry,providing an advanced technological method for precise neuromodulation treatment of patients with mental disorders.However,there is still no unified standard for the clinical application of this technique.Therefore,the Clinical Neurophysiology Branch and the Psychosomatic Medicine Branch of the Medical Association of Henan Province discussed the clinical application of nTMS for the treatment of mental disorders and formed the expert recommendations of navigated transcranial magnetic stimulation for the treatment of mental disorders,which is aimed at providing recommendations for the treatment process and clinical application of nTMS,in order to promote the standardized application and development of this technology in clinical practice.

Nebulization therapy is a direct drug administration process that turns liquid medications into mist that can be inhaled into the lungs and respiratory tract and is an important strategy for various respiratory problems and diseases.In recent years,there has been a high prevalence of respiratory diseases in China,so the popularity of nebulization at home and at basic-level hospitals has increased significantly.Therefore,the standardized application and rational administration of nebulization therapy should be concerned seriously.Led by the Chinese Medical Association Clinical Pharmacy Branch,the updating work of the Expert Consensus on the Rational Use for Inhaled Medicines Administrated by Nebulizers(2024 Edition)was carried out jointly by Chinese Medical Education Association Pharmacy Administration Professional Committee and Clinical Rational Drug Use Professional Committee.This consensus comprehensively introduces the drug delivery characteristics,safety and effectiveness,medication indications,application process and pharmaceutical care of nebulization therapy,the selection of small-volume nebulizers,new drugs for nebulized inhalation,recommended dosing regimens for respiratory diseases,etc.It aims to offer professional guidance for all healthcare providers of standardized nebulization therapy and rational administration.

OBJECTIVE To provide a basis for the rational use of nonsteroidal anti-inflammatory drugs （NSAIDs） in the perioperative period， and provide practical methods and technical references for the evaluation and selection of NSAIDs in medical institutions. METHODS Initiated by the Affiliated Hospital of Qingdao University， Clinical Pharmacy Professional Committee of the Shandong Pharmacists Association， Clinical Individualised Drug Testing and Guidance Branch of the Shandong Medical Association， Comprehensive Clinical Medication Evaluation Working Committee of the Shandong Pharmacists Association， Pain Branch of the Shandong Medical Association in conjunction with several medical institutions in Shandong Province organized 22 pharmaceutical experts and medical experts from 17 hospitals in Shandong Province to form a consensus on the rational use and comprehensive clinical evaluation of NSAIDs in the perioperative period through the literature research method， expert interview method and questionnaire survey method based on evidence-based medicine. A comprehensive clinical evaluation was also conducted on a total of 13 specifications of 9 commonly used clinical drug varieties in Shandong Province， including celecoxib， etoricoxib， imrecoxib， ibuprofen （containing reference/original drugs and national/Shandong Province’s centralized volume-based procurement varieties）. RESULTS & CONCLUSIONS A consensus opinion was formed on preoperative prophylactic use and postoperative use of NSAIDs， as well as contraindications， digestive tract risk， cardiovascular system risk， bleeding risk and kidney injury risk in the perioperative period. The evaluation and selection criteria of perioperative use of NSAIDs were established， involving 6 dimensions of safety， efficacy， economy， innovation， appropriateness， and accessibility. The results of comprehensive clinical evaluation showed that the top 6 drugs （scores over 70） were Celecoxib capsules （Celebrex） and Celecoxib capsules （Naiqi）， Diclofenac sodium sustained-release tablets，Etocoxib tablets （Arcoxia） and Etocoxib tablets （Qimingshu）， and Parecoxib sodium for injection. With the progress of clinical research， this consensus will be further updated and adjusted， and medical institutions can combine with the practice to develop a comprehensive clinical evaluation system of NSAIDs suitable for their institutions.

In order to promote the rational clinical use of gadolinium-based contrast agents （GBCA） and to provide a reference for physicians to prescribe such contrast agents and for pharmacists to review prescriptions， the consensus working group launched the preparation project of “Consensus on whole-process pharmaceutical care for GBCA” according to domestic and foreign guidelines and consensus. The Zhujiang Hospital of Southern Medical University took the lead and cooperated with clinical experts and pharmaceutical experts from several domestic medical institutions to discuss and summarize the basic pharmacological effect of GBCA， types， pharmacokinetics， pharmacodynamics， indications， contraindications， precautions， usage and dosage， adverse drug reactions， and finally forms the consensus. The main contents of this consensus include an overview of various types of GBCA， rational clinical use of drugs， security management and whole-process pharmaceutical care process， etc.， for reference by physicians and pharmacists in medical institutions at all levels.

OBJECTIVE To explore the whole-process pharmaceutical care model of iodine contrast medium and promote the rational clinical use of iodine contrast medium. METHODS Clinical Professional Committee on Rational Drug Use of China Medical Education Association and Expert Committee on Drug Evaluation and Clinical Research of Guangdong Pharmaceutical Association organized domestic experts to establish a working group on the Consensus on the whole-process pharmaceutical care for iodine contrast medium. The working group conducted literature searches， evidence-based analysis， and discussions on the development process， indications， contraindications， adverse drug reactions， drug interactions， drug use for special population， pharmaceutical care， and other key topics to summarize the content and process of the whole-process pharmaceutical care for iodine contrast medium. This consensus was ultimately formed. RESULTS The consensus on whole-process pharmaceutical care for iodine contrast medium included an evaluation of the patient， renal function， combined drug use， and hydration regimen before examination， the presence of contrast agent extravasation or suspected acute adverse reactions during examination， observation time points and follow-up after examination， and the presentation of specific work in each stage through pharmaceutical care flowchart. The medication monitoring record form was also formed to record the work situation. CONCLUSIONS The consensus has established a whole-process pharmaceutical care system for iodine contrast medium， providing scientific evidence for clinical physicians and nursing staff in the rational use of such special drugs， and also serving as a reference for pharmacists in providing related pharmaceutical care.

OBJECTIVE：To provide sugge stions for improving the variety of pediatric drugs and ensuring the safety of pediatric drug use in China. METHODS ：The historical evolution of laws and regulations on the marketing approval of pediatric drugs in the United States and the implementation results of relevant policies were summarized. Combined with the current situation of the development of pediatric drugs in China ，some suggestions were put forward to ensure the accessibility and safety of pediatric drug use in China. RESULTS & CONCLUSIONS ：Since 1994，the United States had issued a series of laws and regulations to encourage the development of pediatric drugs. At present ，the marketing approval of pediatric drugs were mainly based on the two laws of Best Pediatric Drug Act（BPCA）and Pediatric Research Equality Act （PREA）. From 1998 to 2019，the amount of supplements of pediatric drug information in drug instructions of the United States showed a fluctuating growth. As of April 2020，854 kinds of drugs had been modified in pediatric instructions ，792 of which had been carried out post marketing pediatric clinical research ，and the problem of incomplete pediatric instructions had also been greatly improved. At present ，China’s policies on pediatric drugs mainly included encouraging R&D innovation ，giving priority to review and approval ，and strengthening R&D technical guidance. Although certain achievements had been made ，there were still some problems ，such as imperfect policies and regulations ，and great difficulties carrying out pediatric drug clinical trials. It is suggested that our country should draw lessons from the American regulations on pediatric drugs ，pediatric research and the catalogue of pediatric drugs ，and establish a system and catalogue of ped iatric drug use suitable for China ’s national conditions ，so as to improve the effectiveness ，safety and accessibilityof pediatric drugs.

Humans ; Infant, Newborn ; Lung ; Lung Diseases ; diagnostic imaging ; Ultrasonography